NKTR Nektar Therapeutics
$37.97▲ +1.39%
Healthcare
Other
After hours
$37.90▼ -0.18%
Oct 27, 5:51 PM ET
Volume 567.8K
Avg Volume (10D) 904.2K
Key Metrics & Fundamentals
Market Cap
$1.30B
P/E Ratio
–
Div Yield
0.00%
52W Range
33.40 - 109.00
% vs 50 MA
-34.35%
% vs 200 MA
-41.57%
RSI-14
31.2
MACD Histogram
+0.8900
Beta (1Y vs SPY)
0.99
Free Cash Flow
-$75.86M
Gross Rev
$10.13M
Gross Profit
$10.13M
EBITDA
-$32.36M
COGS
–
Operating Exp
$51.89M
Operating Income
-$41.76M
EBIT
-$41.76M
Pretax Income
-$40.30M
Net Income
-$40.62M
EPS (Diluted)
-1.23
Price & Volume History
Loading chart…
Recent News
Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets
PR Newswire · Oct 27, 2026 6:00 PM ET
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · Oct 23, 2026 4:15 PM ET
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?
Zacks · Oct 15, 2026 11:31 AM ET
Nektar Therapeutics (NKTR) Could Be 71% Undervalued As Rezpegaldesleukin Data Extend Its Case
Simply Wall St. · Oct 12, 2026 9:17 AM ET
Leerink Partners Initiates Nektar Therapeutics at Outperform, $130 Price Target
MT Newswires · Oct 12, 2026 6:14 AM ET
Raymond James Initiates Nektar Therapeutics at Market Perform
MT Newswires · Oct 9, 2026 7:28 AM ET
Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang
Insider Monkey · Oct 7, 2026 11:33 AM ET
EADV26: Key late-stage readouts from the conference
Clinical Trials Arena · Oct 5, 2026 7:57 AM ET
Nektar Posted Promising Alopecia Results. Here's Why It Took A 22% Beating.
Investor's Business Daily · Oct 1, 2026 4:29 PM ET
NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge
Stocktwits · Oct 1, 2026 3:42 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See NKTR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.